Eli Lilly and Company returns to Indianapolis after TIDES pharma conference

Eli Lilly and Company's Gulfstream G500, registration N307EL, departed Boston Logan International Airport just after midnight on May 12, 2026, and touched down at Indianapolis International Airport two hours later, cruising at 47,000 feet with a top speed near 472 knots.

The overnight flight capped a swift visit to Boston, where the company dispatched representatives to the TIDES USA 2026 conference running May 11-14. Associate Vice President Michael Kopach presented on synthetic molecule development, as listed in the event program, underscoring Lilly's push into advanced therapeutics amid its dominance in GLP-1 drugs like Mounjaro and Zepbound. Back in Indianapolis, headquarters buzzes with the aftermath of blockbuster first-quarter results, including a 56 percent revenue jump to $19.8 billion per the company's April 30 earnings release.

Such cross-country jaunts mark a busy spring for the pharma leader, with recent flights linking Seattle, Toronto, Denver, San Francisco, New York, and now Boston to its Indiana base—recurring hops to hubs like Washington Dulles and Newark suggest ongoing regulatory and investor engagements in a year of raised profit forecasts and aggressive acquisitions.